Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
(HER2CLIMB) (ONT-380-206), NCT02614794
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The purpose of this study is to assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central review.
MORE DETAILS ON THIS BREAST CANCER TRIAL
16195 / NCT02614794 / PI TBD / STAR Trial / Open 3-30-2017
TRIAL AVAILABLE AT THESE LOCATIONS:
This STAR trial and can be opened at any Location as Patients are identified